Dashboard
1
With ROE of 22.73%, it has a expensive valuation with a 9.49 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 4.17%, its profits have risen by 27.6% ; the PEG ratio of the company is 1.5
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2456.82%
0%
2456.82%
6 Months
3813.04%
0%
3813.04%
1 Year
1053.85%
0%
1053.85%
2 Years
1707.23%
0%
1707.23%
3 Years
924.12%
0%
924.12%
4 Years
1039.24%
0%
1039.24%
5 Years
1710.14%
0%
1710.14%
RaySearch Laboratories AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.20%
EBIT Growth (5y)
35.45%
EBIT to Interest (avg)
16.94
Debt to EBITDA (avg)
1.05
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
1.23
Tax Ratio
22.43%
Dividend Payout Ratio
50.54%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
18.78%
ROE (avg)
8.10%
Valuation key factors
Factor
Value
P/E Ratio
42
Industry P/E
Price to Book Value
9.49
EV to EBIT
30.03
EV to EBITDA
21.84
EV to Capital Employed
14.79
EV to Sales
6.17
PEG Ratio
1.51
Dividend Yield
0.99%
ROCE (Latest)
49.25%
ROE (Latest)
22.73%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Jun 2021
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
304.90
318.90
-4.39%
Operating Profit (PBDIT) excl Other Income
68.70
80.00
-14.12%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
30.80
61.40
-49.84%
Operating Profit Margin (Excl OI)
139.00%
250.90%
-11.19%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -4.39% vs 33.15% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -49.84% vs 463.30% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,192.00
1,022.20
16.61%
Operating Profit (PBDIT) excl Other Income
546.40
406.40
34.45%
Interest
9.00
9.70
-7.22%
Exceptional Items
0.00
0.00
Consolidate Net Profit
203.50
81.60
149.39%
Operating Profit Margin (Excl OI)
207.20%
117.60%
8.96%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 16.61% vs 21.17% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 149.39% vs 242.86% in Dec 2023
About RaySearch Laboratories AB 
RaySearch Laboratories AB
Software Products
RaySearch Laboratories publ AB is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
Company Coordinates 
Company Details
Sveavagen 44, Box 3297 , STOCKHOLM None : 103 65
Registrar Details






